Compare PRE & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRE | IMRX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.7M | 322.8M |
| IPO Year | N/A | 2021 |
| Metric | PRE | IMRX |
|---|---|---|
| Price | $20.54 | $5.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $32.00 | $17.20 |
| AVG Volume (30 Days) | 282.8K | ★ 601.3K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $105.52 | N/A |
| Revenue Next Year | $58.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.09 | $1.10 |
| 52 Week High | $22.86 | $10.08 |
| Indicator | PRE | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 45.94 |
| Support Level | $12.35 | $4.83 |
| Resistance Level | $20.89 | $5.36 |
| Average True Range (ATR) | 1.67 | 0.29 |
| MACD | 0.45 | 0.04 |
| Stochastic Oscillator | 75.65 | 19.64 |
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.